Skip to content

Novartis Says Two Children Getting Spinal Atrophy Drug Have Died

Two children who received Zolgensma, Novartis AG’s gene therapy for a rare condition called spinal muscular atrophy, died from liver complications.

The children died from acute liver failure about six weeks after receiving the infusion of Zolgensma and one to 10 days after tapered doses of a steroid that’s meant to combat liver complications, Novartis said in an emailed statement Thursday. The deaths occurred in Russia and Kazakhstan.